Cargando…

Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China

OBJECTIVE: The ASTRUM-005 trial showed that serplulimab plus chemotherapy (SEP) significantly extended survival time compared with chemotherapy in the treatment of small cell lung cancer. But the survival benefits of SEP came at high costs, and its economy is not clear. Therefore, this study aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Yunchun, Xu, Yuan, Liao, Li, Zhou, Yujie, Wang, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432650/ https://www.ncbi.nlm.nih.gov/pubmed/37586861 http://dx.doi.org/10.1136/bmjopen-2023-072106

Ejemplares similares

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2023)

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
por: Wang, Hao, et al.
Publicado: (2023)

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
por: Khan, Iftekhar, et al.
Publicado: (2015)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

Lifetime quality of life and cost consequences of delays in endovascular treatment for acute ischaemic stroke: a cost-effectiveness analysis from a Singapore healthcare perspective
por: Ni, Weiyi, et al.
Publicado: (2020)

Systematic review of the healthcare cost of bronchopulmonary dysplasia
por: Humayun, Jhangir, et al.
Publicado: (2021)

Societal costs of chemotherapy in the UK: an incidence-based cost-of-illness model for early breast cancer
por: Parsekar, Krishnali, et al.
Publicado: (2021)

Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China
por: Yang, Fei, et al.
Publicado: (2021)

Robot-assisted surgery in a broader healthcare perspective: a difference-in-difference-based cost analysis of a national prostatectomy cohort
por: Hyldgård, Vibe Bolvig, et al.
Publicado: (2017)

Exploring the characteristics of the high-cost population from the family perspective: a cross-sectional study in Jiangsu Province, China
por: Miao, Yudong, et al.
Publicado: (2017)

Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China
por: Xie, Qian, et al.
Publicado: (2022)

Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China
por: Liu, Shixian, et al.
Publicado: (2023)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

End-stage renal disease—financial costs and years of life lost in Panama: a cost-analysis study
por: Moreno Velásquez, Ilais, et al.
Publicado: (2019)

Scoping review of costs of implementation strategies in community, public health and healthcare settings
por: Michaud, Tzeyu L, et al.
Publicado: (2022)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
por: Liu, Qiao, et al.
Publicado: (2020)

Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients
por: Roman, Erin, et al.
Publicado: (2020)

Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
por: Restelli, Umberto, et al.
Publicado: (2017)

Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study
por: Jensen, Manja Dahl, et al.
Publicado: (2020)

Hypertension in the South African public healthcare system: a cost-of-illness and burden of disease study
por: Kohli-Lynch, Ciaran N, et al.
Publicado: (2022)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
por: Wang, Huijuan, et al.
Publicado: (2020)

Modelling the costs and consequences of reducing healthcare-associated infections by improving hand hygiene in an average hospital in England
por: Guest, Julian F, et al.
Publicado: (2019)

Healthcare resource utilisation and cost associated with elevated potassium levels: a Danish population-based cohort study
por: Kim, Kun, et al.
Publicado: (2019)

Healthcare-related cost of oropharyngeal dysphagia and its complications pneumonia and malnutrition after stroke: a systematic review
por: Marin, Sergio, et al.
Publicado: (2020)

Healthcare resource utilisation pattern and costs associated with herpes simplex virus diagnosis and management: a systematic review
por: Lee, Shaun Wen Huey, et al.
Publicado: (2022)

Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study
por: Robinson, Eirin Guldsten, et al.
Publicado: (2022)

Role of healthcare cost accounting in pricing and reimbursement in low-income and middle-income countries: a scoping review
por: Guinness, Lorna, et al.
Publicado: (2022)

Cost-effectiveness of mechanical thrombectomy within 6 hours of acute ischaemic stroke in China
por: Pan, Yuesong, et al.
Publicado: (2018)

Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
por: Shi, Wenchuan, et al.
Publicado: (2021)

Assessing societal and offender perspectives on the value of offender healthcare: a stated preference research protocol
por: Settumba, Stella Nalukwago, et al.
Publicado: (2019)

What are the costs associated with child and maternal healthcare within Australia? A study protocol for the use of data linkage to identify health service use, and health system and patient costs
por: Callander, Emily J, et al.
Publicado: (2018)

Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective
por: Coleman, Craig I, et al.
Publicado: (2015)

Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases
por: Scotti, Lorenza, et al.
Publicado: (2014)

Clinical features and direct medical cost of splenic injury in China: a cross-sectional study
por: Chen, Yong, et al.
Publicado: (2022)

The cost-effectiveness of total laparoscopic hysterectomy compared to total abdominal hysterectomy for the treatment of early stage endometrial cancer
por: Graves, Nicholas, et al.
Publicado: (2013)

Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis
por: Curran, Desmond, et al.
Publicado: (2019)

Healthcare resource utilisation and costs associated with a heart failure diagnosis: a retrospective, population-based cohort study in Sweden
por: Boman, Kurt, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aqotkuv2i5o792sni5jpitskcc